Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CRB037
MIFTS: 71

Cerebral Palsy

Categories: Eye diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Cerebral Palsy

About this section

MalaCards integrated aliases for Cerebral Palsy:

Name: Cerebral Palsy 39 12 77 54 55 30 56 6 44 3 15 17 74
Infantile Cerebral Palsy 12 74
Cerebral Palsy, Mixed 74
Mixed Cerebral Palsy 54
Palsy, Cerebral 41
Palsy Cerebral 77

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases Eye diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:1969
MeSH 45 D002547
NCIt 51 C34460
SNOMED-CT 69 1178005
ICD10 34 G80 G80.9
Sources

Summaries for Cerebral Palsy

About this section
NINDS : 55 The term cerebral palsy refers to a group of neurological disorders that appear in infancy or early childhood and permanently affect body movement, muscle coordination, and balance. CP affects the part of the brain that controls muscle movements.  The majority of children with cerebral palsy are born with it, although it may not be detected until months or years later. The early signs of cerebral palsy usually appear before a child reaches 3 years of age. The most common are a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a “scissored” gait; and muscle tone that is either too stiff or too floppy. Other neurological symptoms that commonly occur in individuals with CP include seizures, hearing loss and impaired vision, bladder and bowel control issues, and pain and abnormal sensations. A small number of children have CP as the result of brain damage in the first few months or years of life, brain infections such as bacterial meningitis or viral encephalitis, or head injury from a motor vehicle accident, a fall, or child abuse. The disorder isn't progressive, meaning that the brain damage typically doesn't get worse over time. Risk factors associated with CP do not cause the disorder but can increase a child's chance of being born with the disorder.CP is not hereditary.

MalaCards based summary : Cerebral Palsy, also known as infantile cerebral palsy, is related to spastic cerebral palsy and inherited congenital spastic tetraplegia, and has symptoms including seizures, tremor and dystonia. An important gene associated with Cerebral Palsy is ADD3 (Adducin 3), and among its related pathways/superpathways are Vesicle-mediated transport and Clathrin derived vesicle budding. The drugs Dexmedetomidine and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include Blood and Umbilical Cord, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 A brain disease that is caused by damage to the motor control centers of the developing brain during pregnancy, during childbirth or after birth, which affects muscle movement and balance.

NIH Rare Diseases : 54 Cerebral palsy refers to a group of neurological disorders that can affect the brain and/or spinal cord. Signs and symptoms generally appear during infancy or early childhood and vary based on the type of cerebral palsy (spastic cerebral palsy, dyskinetic cerebral palsy, ataxic cerebral palsy, and mixed cerebral palsy), the severity of the condition and which area(s) of the brain are affected. Common features include a lack of muscle coordination when performing voluntary movements (ataxia); stiff or tight muscles and exaggerated reflexes (spasticity); walking with one foot or leg dragging; walking on the toes, a crouched gait, or a "scissored" gait; and muscle tone that is either too stiff or too floppy. Cerebral palsy is caused by abnormal brain development or damage to the developing brain. Most of these problems occur as the baby grows in the womb; however, they can happen at any time during the first 2 years of life. There is no cure for cerebral palsy, but treatment is available to alleviate some symptoms. This may include physical, occupational, and speech therapy; certain medications; surgery; and/or devices (i.e. braces, wheelchairs) to aid in mobility.

MedlinePlus : 44 Cerebral palsy is a group of disorders that affect a person's ability to move and to maintain balance and posture. The disorders appear in the first few years of life. Usually they do not get worse over time. People with cerebral palsy may have difficulty walking. They may also have trouble with tasks such as writing or using scissors. Some have other medical conditions, including seizure disorders or mental impairment. Cerebral palsy happens when the areas of the brain that control movement and posture do not develop correctly or get damaged. Early signs of cerebral palsy usually appear before 3 years of age. Babies with cerebral palsy are often slow to roll over, sit, crawl, smile, or walk. Some babies are born with cerebral palsy; others get it after they are born. There is no cure for cerebral palsy, but treatment can improve the lives of those who have it. Treatment includes medicines, braces, and physical, occupational and speech therapy. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 77 Cerebral palsy (CP) is a group of permanent movement disorders that appear in early childhood. Signs and... more...

Sources

Related Diseases for Cerebral Palsy

About this section

Diseases related to Cerebral Palsy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 500)
# Related Disease Score Top Affiliating Genes
1 spastic cerebral palsy 34.4 F5 GAD1 PLP1
2 inherited congenital spastic tetraplegia 33.3 ADD3 GAD1 KANK1
3 spastic paraplegia 50, autosomal recessive 33.0 AP4B1 AP4M1 AP4S1
4 hypertonia 32.6 AP4B1 AP4M1 AP4S1
5 hereditary spastic paraplegia 51 32.1 AP4B1 AP4S1
6 hereditary spastic paraplegia 32.0 AP4B1 AP4M1 ATL1 PLP1
7 spastic paraplegia 2, x-linked 32.0 AP4B1 ATL1 PLP1
8 disease of mental health 30.7 APOE GAD1 IL6
9 leukomalacia 30.6 IL6 TNF
10 chorioamnionitis 30.3 IL1B IL6 MMP8 TNF
11 thrombophilia 30.2 F2 F5 MTHFR
12 placental abruption 30.1 F2 F5 MTHFR
13 stroke, ischemic 30.1 APOE F2 F5 MTHFR
14 eclampsia 30.0 F2 MTHFR TNF
15 arthritis 30.0 IL1B IL6 LTA TNF
16 pre-eclampsia 30.0 F2 F5 IL6 MTHFR
17 cytomegalovirus infection 29.9 IL1B IL6 TNF
18 gingivitis 29.8 IL1B IL6 MMP8 TNF
19 juvenile rheumatoid arthritis 29.8 IL1B IL6 LTA TNF
20 bacterial vaginosis 29.8 IL1B IL6 TNF
21 pyelonephritis 29.8 IL1B IL6 TNF
22 porencephaly 29.7 COL4A1 F2 F5 MTHFR
23 periodontitis, chronic 29.7 IL1B IL6 MMP8
24 schizencephaly 29.7 COL4A1 F5 MTHFR
25 periodontal disease 29.7 IL1B IL6 MMP8 TNF
26 placenta disease 29.7 F5 IL1B IL6 MTHFR
27 sleep apnea 29.7 APOE IL1B IL6 TNF
28 preterm premature rupture of the membranes 29.7 IL1B IL6 MMP8
29 peritonitis 29.6 F2 IL1B IL6 TNF
30 multiple sclerosis 29.5 APOE IL1B IL6 LTA PLP1 TNF
31 periodontitis 29.5 IL1B IL6 MMP8 TNF
32 cerebral palsy, ataxic, autosomal recessive 12.9
33 dyskinetic cerebral palsy 12.8
34 spastic diplegia cerebral palsy 12.7
35 cerebral palsy, spastic quadriplegic, 1 12.7
36 cerebral palsy, spastic quadriplegic, 2 12.6
37 cerebral palsy, spastic quadriplegic, 3 12.6
38 mixed cerebral palsy 12.5
39 spastic quadriplegia 12.5
40 spastic hemiplegia 12.4
41 cerebral palsy athetoid 12.4
42 spastic diplegia 12.4
43 spastic monoplegia 12.2
44 intellectual disability - athetosis - microphthalmia 12.0
45 spastic paraplegia 47, autosomal recessive 11.8
46 spastic paraplegia 52, autosomal recessive 11.8
47 spastic paraplegia 51, autosomal recessive 11.7
48 periventricular leukomalacia 11.6
49 spasticity 11.6
50 suprabulbar paresis, congenital 11.5

Comorbidity relations with Cerebral Palsy via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Cerebral Palsy:



Diseases related to Cerebral Palsy
Sources

Symptoms & Phenotypes for Cerebral Palsy

About this section

UMLS symptoms related to Cerebral Palsy:


seizures, tremor, dystonia, back pain, pain, headache, abnormality of extrapyramidal motor function, involuntary movements, torticollis, muscle fibrillation, syncope, athetosis, myokymia, chronic pain, sciatica, vertigo/dizziness, sleeplessness, muscle rigidity, asterixis

MGI Mouse Phenotypes related to Cerebral Palsy:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.23 AP4B1 AP4E1 APOE ATL1 COL4A1 F2
2 homeostasis/metabolism MP:0005376 10.21 AP4E1 AP4M1 APOE COL4A1 F2 F5
3 growth/size/body region MP:0005378 10.18 AP4E1 APOE COL4A1 F2 F5 GAD1
4 cardiovascular system MP:0005385 10.13 ADD3 AP4E1 APOE COL4A1 F2 F5
5 nervous system MP:0003631 10.07 AP4B1 AP4E1 APOE COL4A1 F2 F5
6 limbs/digits/tail MP:0005371 9.87 AP4E1 APOE ATL1 GAD1 LTA MTHFR
7 respiratory system MP:0005388 9.7 APOE COL4A1 F2 GAD1 IL6 LTA
8 skeleton MP:0005390 9.65 AP4E1 APOE F2 GAD1 IL1B IL6
9 vision/eye MP:0005391 9.23 AP4E1 APOE COL4A1 IL6 LTA MTHFR
Sources

Drugs & Therapeutics for Cerebral Palsy

About this section

Drugs for Cerebral Palsy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 246)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
2
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
3
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
4
Levodopa Approved Phase 4 59-92-7 6047
5
Acetylcholine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 51-84-3 187
6
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 7487-88-9 24083
7
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
8
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1 1134-47-0 2284
9
Bupivacaine Approved, Investigational Phase 4,Not Applicable 38396-39-3, 2180-92-9 2474
10
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
11
Acetaminophen Approved Phase 4 103-90-2 1983
12
Desipramine Approved, Investigational Phase 4 50-47-5 2995
13
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
14
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 7440-70-2 271
15
Inulin Approved, Investigational, Nutraceutical Phase 4 9005-80-5 24763
16 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
17 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
18 Adrenergic Agonists Phase 4,Phase 2,Phase 1
19 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 1
20 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
21 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
22 Anesthetics, Inhalation Phase 4,Not Applicable
23 Adrenergic alpha-Agonists Phase 4,Phase 1
24 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Platelet Aggregation Inhibitors Phase 4,Not Applicable
27 Anesthetics, General Phase 4,Not Applicable
28 Analgesics, Non-Narcotic Phase 4,Phase 3,Not Applicable
29 Hypnotics and Sedatives Phase 4,Not Applicable
30 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Cardiotonic Agents Phase 4,Phase 2
32 Sympathomimetics Phase 4,Phase 2
33 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Dihydroxyphenylalanine Phase 4
35 Carbidopa, levodopa drug combination Phase 4
36 Dopamine Agents Phase 4
37 Botulinum Toxins Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 abobotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Neuromuscular Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 Acetylcholine Release Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Tocolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 calcium channel blockers Phase 4,Phase 3,Phase 2,Not Applicable
45 Anti-Arrhythmia Agents Phase 4,Phase 3,Phase 2,Not Applicable
46 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
47 Calcium, Dietary Phase 4,Phase 3,Phase 2,Not Applicable
48 Anticonvulsants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Hematinics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 incobotulinumtoxinA Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 801)
# Name Status NCT ID Phase Drugs
1 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
2 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
3 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
4 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
5 Clinical Study of Xingnaojing for the Treatment of Convulsive Diseases Unknown status NCT00796380 Phase 4 Xingnaojing
6 Alterations of Functional Activities and Leg Stiffness After Hamstring Lengthening in Cerebral Palsy Children Completed NCT00154830 Phase 4
7 Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy Completed NCT01276015 Phase 4 Botulinum Toxin Type A
8 Efficacy and Safety of Meditoxin® Injection for Cervical Dystonia in Adults With Cerebral Palsy Completed NCT01860196 Phase 4 Meditoxin;Normal saline
9 Postoperative Pain in Children With Cerebral Palsy After Pelvic and Femoral Osteotomies Completed NCT00964639 Phase 4 Ropivacaine;Saline
10 Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
11 Synbiotic, Prebiotics and Probiotics in Children With Cerebral Palsy and Constipation Completed NCT03117322 Phase 4
12 Recurrent Crying Spells in Cerebral Palsy Completed NCT01955655 Phase 4 Baclofen
13 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Completed NCT01256021 Phase 4 Botulinum Toxin Type A
14 Neuroprotection by Magnesium Sulfate Given to Women at Risk of Very Preterm Birth Completed NCT00120588 Phase 4 magnesium
15 Effects of Transfusion Thresholds on Neurocognitive Outcome of Extremely Low Birth Weight Infants Completed NCT01393496 Phase 4
16 Effect of Erythropoietin on Preterm Brain Injury Completed NCT02036073 Phase 4 recombinant human erythropoietin
17 A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants Completed NCT00756600 Phase 4 Regional Anesthesia;General Anesthesia
18 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
19 Paracetamol Study in Patients With Low Muscle Mass Recruiting NCT03648658 Phase 4 Paracetamol 120Mg/5mL Oral Suspension
20 Intrathecal (IT) Baclofen Drug Distribution Recruiting NCT02903823 Phase 4 Baclofen bolus injection
21 A Pilot Study of Dexmedetomidine-Propofol in Children Undergoing Magnetic Resonance Imaging Active, not recruiting NCT02633241 Phase 4 Dexmedetomidine-Propofol
22 Desipramine in Infantile Neuroaxonal Dystrophy (INAD). Enrolling by invitation NCT03726996 Phase 4 Desipramine
23 Changes of Gas Values in Cord Blood Versus Time and Temperature Not yet recruiting NCT02785367 Phase 4
24 Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy Terminated NCT00549471 Phase 4
25 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Terminated NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
26 Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy Withdrawn NCT01386255 Phase 4 Baclofen;placebo
27 Safety and Efficacy of Bone Marrow MNC for the Treatment of Cerebral Palsy in Subjects Below 15 Years Unknown status NCT01832454 Phase 2, Phase 3
28 Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy Unknown status NCT01489904 Phase 2, Phase 3
29 Targeted Hip Strength Training in Children With Cerebral Palsy (CP) Unknown status NCT01633736 Phase 3
30 Modulation of Brain Plasticity After Perinatal Stroke Unknown status NCT01189058 Phase 2, Phase 3
31 Project:Intensive Habilitation (PIH) Unknown status NCT00202761 Phase 2, Phase 3
32 Magnesium Sulfate to Prevent Brain Injury in Premature Infants Unknown status NCT00065949 Phase 3 magnesium sulfate
33 Efficacy Study of Hypothermia Plus Magnesium Sulphate(MgSO4) in the Management of Term and Near Term Babies With Hypoxic Ischemic Encephalopathy Unknown status NCT01646619 Phase 3 Magnesium Sulphate;Placebo
34 Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy Completed NCT01787344 Phase 3 Botulinum Toxin Type A(Botox®);Botulinum toxin type A(Botulax®)
35 Orthotics in Ambulatory Cerebral Palsy Completed NCT01527162 Phase 3
36 The Post-Operative Pain in Cerebral Palsy (POPPIES) Trial Completed NCT01437644 Phase 3 botulinum toxin intramuscular injection
37 Efficacy and Functional Outcomes of Botulinum Toxin A Injections to Hamstrings in Flexed Knee Gait in Cerebral Palsy Completed NCT00261131 Phase 3 Botulinum Toxin A
38 Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Patients With Cerebral Paralysis Completed NCT01929434 Phase 3
39 Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy Completed NCT01893411 Phase 3 IncobotulinumtoxinA (16 Units per kg body weight);IncobotulinumtoxinA (12 Units per kg body weight);IncobotulinumtoxinA (4 Units per kg body weight)
40 Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy Completed NCT01905683 Phase 3 IncobotulinumtoxinA (16-20 Units per kg body weight)
41 Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy Completed NCT02002884 Phase 3 IncobotulinumtoxinA (8 Units per kg body weight);IncobotulinumtoxinA (6 Units per kg body weight);IncobotulinumtoxinA (2 Units per kg body weight)
42 Dutch National ITB Study in Children With Cerebral Palsy Completed NCT00367068 Phase 3 baclofen, intrathecal
43 Static and Dynamic Postural Stability in Cerebral Palsy Children Completed NCT01799304 Phase 3
44 A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years Completed NCT01898520 Phase 3 Sativex;Placebo
45 Efficacy of Intermittent Serial Casting on Spastic Wrist Flexion Deformity Completed NCT03306212 Phase 3 Botulinum toxin A
46 Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Completed NCT00491894 Phase 3 Oral Glycopyrrolate Liquid
47 Botulinum Toxin Efficiency on Spasticity of Rectus Femoris and Semitendinosus Muscles as Functional Agonist and Antagonist Muscles Completed NCT00133861 Phase 2, Phase 3 Botulinum toxin
48 Dysport® Pediatric Lower Limb Spasticity Follow-on Study Completed NCT01251380 Phase 3 Botulinum type A toxin (Dysport®)
49 Dysport® Pediatric Lower Limb Spasticity Study Completed NCT01249417 Phase 3 Botulinum type A toxin (Dysport®);Placebo
50 Beneficial Effects of Antenatal Magnesium Sulfate (BEAM Trial) Completed NCT00014989 Phase 3 magnesium sulfate

Search NIH Clinical Center for Cerebral Palsy

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Cerebral Palsy cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Cerebral Palsy:
Bone marrow-derived mononuclear cells for the treatment of cerebral palsy
Umbilical cord-derived mesenchymal stem cells for treatment of cerebral palsy
Embryonic/Adult Cultured Cells Related to Cerebral Palsy:
Umbilical cord-derived mesenchymal stem cells (family)
Sources

Genetic Tests for Cerebral Palsy

About this section

Genetic tests related to Cerebral Palsy:

# Genetic test Affiliating Genes
1 Cerebral Palsy 30
Sources

Anatomical Context for Cerebral Palsy

About this section

MalaCards organs/tissues related to Cerebral Palsy:

42
Brain, Bone, Testes, Spinal Cord, Eye, Heart, Bone Marrow
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Cerebral Palsy:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Cord Blood Mesenchymal Stem Cells Potential therapeutic candidate
2 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate
Sources

Publications for Cerebral Palsy

About this section

Articles related to Cerebral Palsy:

(show top 50) (show all 4738)
# Title Authors Year
1
A systematic review of comorbidity between cerebral palsy, autism spectrum disorders and Attention Deficit Hyperactivity Disorder. ( 30446273 )
2019
2
Using Artificial Intelligence to Identify Factors Associated with Autism Spectrum Disorder in Adolescents with Cerebral Palsy. ( 31018221 )
2019
3
Comparing differences in support needs as perceived by parents of adult offspring with down syndrome, autism spectrum disorder and cerebral palsy. ( 30101573 )
2019
4
Peer support interventions for individuals with acquired brain injury, cerebral palsy, and spina bifida: a systematic review. ( 31068184 )
2019
5
Early prediction of unilateral cerebral palsy in infants with asymmetric perinatal brain injury - Model development and internal validation. ( 31078397 )
2019
6
Development and validation of a screening tool for feeding/swallowing difficulties and undernutrition in children with cerebral palsy. ( 30937885 )
2019
7
Can Neonatal Systemic Inflammation and Hypoxia Yield a Cerebral Palsy-Like Phenotype in Periadolescent Mice? ( 30941732 )
2019
8
Prescribing upper limb orthoses for children with cerebral palsy: a Q methodology study of occupational therapists' decision making. ( 30973762 )
2019
9
Normative values and discriminative ability across functional levels of ACTIVLIM-CP, a measure of global activity performance for children with cerebral palsy. ( 30973788 )
2019
10
Effects of robotic rehabilitation on walking and balance in pediatric patients with hemiparetic cerebral palsy. ( 30974395 )
2019
11
High-density electromyographic data during isometric contractions of the ankle joint in children with cerebral palsy pre and post BoNT-A treatment. ( 30976636 )
2019
12
3-D lower extremity bone morphology in ambulant children with cerebral palsy and its relation to gait. ( 30978527 )
2019
13
Ethics of human enhancement in cerebral palsy. ( 30978528 )
2019
14
Reliability of single-day walking performance and physical activity measures using inertial sensors in children with cerebral palsy. ( 30978529 )
2019
15
Virtual Reality Enhances Gait in Cerebral Palsy: A Training Dose-Response Meta-Analysis. ( 30984095 )
2019
16
Vaccination Status of Children With Epilepsy or Cerebral Palsy in Hunan Rural Area and a Relative KAP Survey of Vaccinators. ( 30984716 )
2019
17
Outcomes in adults with cerebral palsy: systematic review using the International Classification of Functioning, Disability and Health. ( 30985004 )
2019
18
Effect of dance on lower-limb range of motion in young people with cerebral palsy: a blinded randomized controlled clinical trial. ( 30988649 )
2019
19
Does nuchal cord at birth increase the risk for cerebral palsy? ( 30991236 )
2019
20
Novel approaches to measuring community integration in adults with cerebral palsy. ( 30994013 )
2019
21
Comparison of gait with and without ankle-foot orthoses after lower limb surgery in children with unilateral cerebral palsy. ( 30996743 )
2019
22
Impact of tranexamic acid use on blood loss and transfusion rates following femoral varus derotational osteotomy in children with cerebral palsy. ( 30996744 )
2019
23
Hip Surveillance in Children With Cerebral Palsy. ( 30998565 )
2019
24
Performance of stair negotiation in patients with cerebral palsy and stiff knee gait. ( 30999269 )
2019
25
Effect of Positioning on Tonic Labyrinthine Reflex in Cerebral Palsy: A Single-centre Study from Lahore. ( 31000848 )
2019
26
Systematic Review: Long-term cognitive and behavioural outcomes of neonatal hypoxic-ischaemic encephalopathy in children without cerebral palsy. ( 31002422 )
2019
27
Effects of virtual reality in body oscillation and motor performance of children with cerebral palsy: A preliminary randomized controlled clinical trial. ( 31003657 )
2019
28
Rehabilitation with a combination of scalp acupuncture and exercise therapy in spastic cerebral palsy. ( 31003673 )
2019
29
Femoral derotation osteotomy in children with cerebral palsy using the pediatric proximal femoral nail. ( 31008810 )
2019
30
Factors Influencing Motor Outcome of Hippotherapy in Children with Cerebral Palsy. ( 31009955 )
2019
31
Aberrant Interhemispheric Functional Organization in Children with Dyskinetic Cerebral Palsy. ( 31011574 )
2019
32
Risk factors associated with epilepsy development in children with cerebral palsy. ( 31011806 )
2019
33
Development of a robotic walker for individuals with cerebral palsy. ( 31012754 )
2019
34
Visuo-haptic transfer for object recognition in children with periventricular leukomalacia and bilateral cerebral palsy. ( 31017037 )
2019
35
Understanding the factors that impact the participation in physical activity and recreation in young adults with cerebral palsy (CP). ( 31018910 )
2019
36
Tuberculous peritonitis in a cerebral palsy patient: A challenge in diagnosis and management. ( 31022625 )
2019
37
International expert recommendations of clinical features to prompt referral for diagnostic assessment of cerebral palsy. ( 31025318 )
2019
38
Obstetric factors associated with uterine rupture in mothers who deliver infants with cerebral palsy. ( 31032674 )
2019
39
Examination of touch-coordinate errors of adolescents with unilateral spastic cerebral palsy at an aiming-tapping task. ( 31033458 )
2019
40
Is there evidence of benefits associated with dancing in children and adults with cerebral palsy? A scoping review. ( 30973761 )
2019
41
A Critical Evaluation of Current Concepts in Cerebral Palsy. ( 30968751 )
2019
42
Genetic or Other Causation Should Not Change the Clinical Diagnosis of Cerebral Palsy. ( 30963790 )
2019
43
The Validity and Reliability of a Kinect v2-Based Gait Analysis System for Children with Cerebral Palsy. ( 30959970 )
2019
44
Dyke-Davidoff-Masson syndrome: unusual cause of hemiplegic cerebral palsy. ( 30954966 )
2019
45
Selective dorsal rhizotomy improves muscle forces during walking in children with spastic cerebral palsy. ( 30953917 )
2019
46
Cerebral palsy prevalence, subtypes, and associated impairments: a population-based comparison study of adults and children. ( 30950519 )
2019
47
Adults with cerebral palsy: findings from a population-based register. ( 30950510 )
2019
48
Pharmacological management of abnormal tone and movement in cerebral palsy. ( 30948360 )
2019
49
The effect of combined functional anaerobic and strength training on treadmill gait kinematics and kinetics in ambulatory young adults with cerebral palsy. ( 30947107 )
2019
50
Stander use for an adolescent with cerebral palsy at GMFCS level V with hip and knee contractures. ( 30945990 )
2019
Sources

Variations for Cerebral Palsy

About this section

ClinVar genetic disease variations for Cerebral Palsy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ADD3 NM_016824.4(ADD3): c.1100G> A (p.Gly367Asp) single nucleotide variant Pathogenic rs564185858 GRCh37 Chromosome 10, 111882007: 111882007
2 ADD3 NM_016824.4(ADD3): c.1100G> A (p.Gly367Asp) single nucleotide variant Pathogenic rs564185858 GRCh38 Chromosome 10, 110122249: 110122249
3 46;XX;t(1;5)(p31;q33)dn Translocation Likely pathogenic
4 46;XY;t(6;16)(p21.1;q21)dn Translocation Uncertain significance
Sources

Expression for Cerebral Palsy

About this section
Search GEO for disease gene expression data for Cerebral Palsy.
Sources

Pathways for Cerebral Palsy

About this section

Pathways related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Vesicle-mediated transport 67
Show member pathways
 13.28 AP4B1 AP4E1 AP4M1 AP4S1 APOE COL4A1
2
Clathrin derived vesicle budding 67
Show member pathways
 12.31 AP4B1 AP4E1 AP4M1 AP4S1
3
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.07 IL1B IL6 PLP1 TNF
4
Th1 Differentiation Pathway 66
Show member pathways
 11.96 IL1B IL6 LTA TNF
5
Lysosome 38
11.9 AP4B1 AP4E1 AP4M1 AP4S1
6
Spinal Cord Injury 1
11.86 COL4A1 IL1B IL6 TNF
7
NF-kappa B signaling pathway 38
11.83 IL1B LTA TNF
8
Hematopoietic cell lineage 38
11.82 IL1B IL6 TNF
9
Rheumatoid arthritis 38
11.78 IL1B IL6 TNF
10
TNF signaling pathway 38
11.78 IL1B IL6 LTA TNF
11
Selenium Micronutrient Network 1
Show member pathways
 11.77 APOE F2 IL1B IL6 MTHFR TNF
12
Innate Lymphoid Cell Differentiation Pathways 66
11.72 IL1B LTA TNF
13
AGE-RAGE signaling pathway in diabetic complications 38
11.71 COL4A1 IL1B IL6 TNF
14
Pertussis 38
11.68 IL1B IL6 TNF
15
Dendritic Cells Developmental Lineage Pathway 66
11.66 IL1B IL6 TNF
16
Amoebiasis 38
11.65 COL4A1 IL1B IL6 TNF
17
Microglia Activation During Neuroinflammation: Overview 66
Show member pathways
 11.65 COL4A1 F2 IL1B IL6 TNF
18
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.64 IL1B IL6 TNF
19
Lung fibrosis 1
11.58 IL1B IL6 TNF
20
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.57 IL1B IL6 TNF
21
Legionellosis 38
11.5 IL1B IL6 TNF
22
Interleukin-10 signaling 67
11.44 IL1B IL6 TNF
23
Malaria 38
11.43 IL1B IL6 TNF
24
African trypanosomiasis 38
11.28 IL1B IL6 TNF
25
IL-10 Pathway 65
11.24 IL1B IL6 TNF
26
Transcription_Role of VDR in regulation of genes involved in osteoporosis 23
11.21 APOE IL1B IL6 TNF
27
Development and heterogeneity of the ILC family 1
11.18 IL1B IL6 TNF
28
G-protein signaling_RhoB regulation pathway 23
11.12 IL1B IL6 LTA TNF
29
Cytokines and Inflammatory Response 1
11.1 IL1B IL6 TNF
30
G-protein signaling_Rap2B regulation pathway 23
10.95 COL4A1 IL1B IL6 LTA TNF
31
Overview of nanoparticle effects 1
10.78 COL4A1 IL6 TNF
32
Antifolate resistance 38
10.42 IL1B IL6 MTHFR TNF
Sources

GO Terms for Cerebral Palsy

About this section

Cellular components related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.97 APOE COL4A1 F2 F5 IL1B IL6
2 endoplasmic reticulum lumen GO:0005788 9.65 APOE COL4A1 F2 F5 IL6
3 trans-Golgi network membrane GO:0032588 9.46 AP4B1 AP4E1 AP4M1 AP4S1
4 endosome lumen GO:0031904 9.26 AP4B1 AP4E1 AP4M1 AP4S1
5 AP-4 adaptor complex GO:0030124 8.92 AP4B1 AP4E1 AP4M1 AP4S1
6 extracellular region GO:0005576 10.02 APOE COL4A1 F2 F5 IL1B IL6

Biological processes related to Cerebral Palsy according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.99 IL1B IL6 MMP8 PLP1 TNF
2 cellular protein metabolic process GO:0044267 9.92 APOE F2 F5 IL6
3 defense response to Gram-positive bacterium GO:0050830 9.82 IL6 LTA TNF
4 positive regulation of JNK cascade GO:0046330 9.81 IL1B MMP8 TNF
5 humoral immune response GO:0006959 9.75 IL6 LTA TNF
6 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.74 IL1B MMP8 TNF
7 positive regulation of interferon-gamma production GO:0032729 9.71 IL1B LTA TNF
8 positive regulation of nitric oxide biosynthetic process GO:0045429 9.7 IL1B MMP8 TNF
9 protein localization GO:0008104 9.67 AP4B1 AP4E1 AP4M1 AP4S1
10 negative regulation of growth of symbiont in host GO:0044130 9.65 LTA TNF
11 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.65 IL1B TNF
12 locomotory exploration behavior GO:0035641 9.64 APOE GAD1
13 negative regulation of lipid storage GO:0010888 9.63 IL6 TNF
14 negative regulation of platelet activation GO:0010544 9.62 APOE F2
15 response to glucocorticoid GO:0051384 9.61 IL6 TNF
16 positive regulation of chemokine biosynthetic process GO:0045080 9.6 IL1B TNF
17 regulation of establishment of endothelial barrier GO:1903140 9.58 IL1B TNF
18 negative regulation of neurogenesis GO:0050768 9.58 IL1B IL6 TNF
19 positive regulation of fever generation GO:0031622 9.56 IL1B TNF
20 positive regulation of interleukin-6 production GO:0032755 9.56 IL1B IL6 MMP8 TNF
21 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.55 LTA TNF
22 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.5 APOE IL1B TNF
23 sequestering of triglyceride GO:0030730 9.49 IL1B TNF
24 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.48 IL1B TNF
25 regulation of microglial cell activation GO:1903978 9.46 MMP8 TNF
26 protein targeting GO:0006605 9.46 AP4B1 AP4E1 AP4M1 AP4S1
27 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.43 LTA TNF
28 positive regulation of glial cell proliferation GO:0060252 9.26 IL1B IL6 LTA TNF
29 chronic inflammatory response to antigenic stimulus GO:0002439 9.21 TNF
30 positive regulation of neuroinflammatory response GO:0150078 8.92 IL1B IL6 MMP8 TNF
31 regulation of signaling receptor activity GO:0010469 10.01 F2 IL1B IL6 LTA TNF

Molecular functions related to Cerebral Palsy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 8.92 IL1B IL6 LTA TNF
Sources

Sources for Cerebral Palsy

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....